fbpx
    • Featured
    • Multiple Myeloma News
    • Past Myeloma Crowd Round Tables
    • Apr 26, 2018

    MCRT: Baltimore, Maryland–March 28, 2018

On March 28, 2018, a Myeloma Crowd Round Table meeting was held in Baltimore, Maryland with a group of four regional myeloma experts, including:

  • Dr. Ashraf Badros, University of Maryland Greenebaum Cancer Center
  • Dr. Ivan Borrello, The Johns Hopkins School of Medicine
  • Dr. William Matsui, The Johns Hopkins School of Medicine
  • Dr. David Vesole, Georgetown University/Hackensack University Medical Center

David Vesole, MD: Bone Disease and Multiple Myeloma Risk Stratification

 

Dr. Vesole: YouTube
Dr. Vesole speaks about the bone disease that affects 85% of multiple myeloma patients, and how bone hardening medicines may be the most important intervention in improving the life of myeloma patients.

Ashraf Badros, MD: The Future of Multiple Myeloma

 

Dr. Badros: YouTube
Dr. Badros believes the future of myeloma is to focus on high risk multiple myeloma patients. Better measures of disease progression, earlier therapy, improved imaging and new drugs and therapies will create a paradigm shift to improve patient outcomes.

Ashraf Badros, MD: Multiple Myeloma Therapy Paradigm Shift

 

Dr. Badros: YouTube pt. 2
Dr. Badros speaks about current exciting developments that are transforming the standard of care today in the treatment of multiple myeloma.

Ivan Borrello, MD: Immunotherapy for Multiple Myeloma

 

Dr. Borrello: YouTube
Dr. Borrello speaks about the integration of immunotherapy treatments into myeloma therapy. Immunotherapies have the potential to use the immune system to prevent disease progression and improve response to treatment with existing drugs. Checkpoint inhibitors, IMiDs, vaccines and CAR-T cells are revolutionizing the field of immunotherapy and present promising opportunities for the future.

Ivan Borrello, MD: Evolution of Multiple Myeloma

 

Dr. Borrello: YouTube pt. 2
Dr. Borrello talks about the genetic evolution of myeloma, from a single plasma cell to multiple myeloma and plasma cell leukemia, as well as MRD negativity and transplant.

Expert Panel Q&A: Multiple Myeloma (Morning Session)

 

Morning Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:

  • 0:11 What are the criteria for getting a transplant and when do you do it?
  • 5:02 What’s the difference between chromosomal hyperdiploidy, deletions and translocations?
  • 7:40 How does age affect the decision to get a transplant?
  • 9:01 What about patients who experience a partial response?
  • 13:02 Why can bone breaks occur even when taking bone strengtheners?
  • 14:32 Should someone with an 11:14 translocation take Venetoclax for maintenance therapy?
  • 15:44 What bone tests should I do?
  • 17:21 How do doctors decide maintenance regimens for their patients?
  • 23:00 I had an autologous transplant and relapsed – should I do an allo transplant?
  • 27:53 Should FISH tests be repeated since myeloma genetics change over time?
  • 30:34 Are there studies looking at Darzalex or Rev/Dex for maintenance?

Expert Panel Q&A: Multiple Myeloma (Afternoon Session)

 

Afternoon Q&A: YouTube
Multiple Myeloma experts Ashraf Badros, MD, Ivan Borrello, MD and David Vesole, MD, PhD answer questions from the audience during the afternoon session of the Myeloma Crowd Round Table in Baltimore. Topics covered include:

  • 0:11 How does race play a role in multiple myeloma?
  • 4:00 Are there alternative or dietary ways to treat or manage myeloma?
  • 7:11 Can we detect smoldering myeloma early?
  • 9:44 What does my genetic translocation mean?
  • 10:41 If two transplants is better than one, how many transplants can be done in a lifetime?
  • 13:13 What is the best way to determine the success of a stem cell transplant?
  • 14:22 Time in remission after transplants gets shorter. Does this happen with other therapies as well?
  • 15:38 Should someone with smoldering myeloma seek treatment before it progresses?
  • 15:59 Does myeloma change the way it acts biologically over time?
  • 17:05 In regular urine testing, what should I look for in those tests?

About Author

MYELOMA CROWD RESEARCH INITIATIVE
$99,715 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal
AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: